INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $50,000 Investing In AcelRx Pharmaceuticals, Inc. (ACRX) To Contact The Firm

News provided by

Oct 03, 2014, 04:19 ET

NEW YORK, Oct. 3, 2014 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) of the December 1, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against AcelRx and certain executives.

A complaint has been filed in the United States District Court for the Northern District of California on behalf of all persons who purchased or otherwise acquired AcelRx common stock and/or call options, or sold/wrote AcelRx put options between December 2, 2013 and September 25, 2014, inclusive (the "Class Period").

The complaint alleges that the Company and its executives violated federal securities laws with respect to its disclosures concerning its business, operations, and prospects.

Specifically, the action alleges that during the Class Period, AcelRx made false and/or misleading statements and/or failed to disclose that (i) the designs in the Instructions for Use of the Zalviso System ("Zalviso") did not adequately address the risk of the inadvertent misplacement of tablets; and (ii) the Company did not submit sufficient data to the FDA in order to support the shelf life of the product.

On September 26, 2014, AcelRx announced that the resubmission process for its Zalviso New Drug Application would not be complete until the first quarter of 2015 at the earliest.

Following this news, the price of AcelRx stock declined by $1.31, or over 19%, to close at $5.41 on September 26, 2014.

Request more information now by clicking here: www.faruqilaw.com/ACRX. There is no cost or obligation to you.

Take Action

If you invested in AcelRx stock or options between December 2, 2013 and September 25, 2014 and would like to discuss your legal rights, visit www.faruqilaw.com/ACRX. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected]. Faruqi & Faruqi, LLP also encourages anyone with information regarding AcelRx's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients. To keep track of the latest securities litigation news, follow us on Twitter at www.twitter.com/MergerActivity or on Facebook at www.facebook.com/FaruqiLaw.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
[email protected]
Telephone: (877) 247-4292 or (212) 983-9330

Logo - http://photos.prnewswire.com/prnh/20120119/MM38856LOGO

SOURCE Faruqi & Faruqi, LLP